These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
123 related articles for article (PubMed ID: 2154921)
21. Phase II trial of etoposide in leiomyosarcoma of the uterus: a Gynecologic Oncology Group study. Thigpen T; Blessing JA; Yordan E; Valea F; Vaccarello L Gynecol Oncol; 1996 Oct; 63(1):120-2. PubMed ID: 8898180 [TBL] [Abstract][Full Text] [Related]
23. Mitoxantrone in the treatment of advanced vulvar and vaginal carcinoma. A gynecologic oncology group study. Muss HB; Bundy BN; Christopherson WA Am J Clin Oncol; 1989 Apr; 12(2):142-4. PubMed ID: 2705404 [TBL] [Abstract][Full Text] [Related]
24. A phase II clinical trial of diaziquone (AZQ) in the treatment of patients with recurrent leiomyosarcoma of the uterus. A Gynecologic Oncology Group study. Slayton RE; Blessing JA; Look K; Anderson B Invest New Drugs; 1991 May; 9(2):207-8. PubMed ID: 1874603 [TBL] [Abstract][Full Text] [Related]
25. Combination chemotherapy with hydroxyurea, dacarbazine (DTIC), and etoposide in the treatment of uterine leiomyosarcoma: a Gynecologic Oncology Group study. Currie J; Blessing JA; Muss HB; Fowler J; Berman M; Burke TW Gynecol Oncol; 1996 Apr; 61(1):27-30. PubMed ID: 8626112 [TBL] [Abstract][Full Text] [Related]
26. Systemic therapy for advanced uterine sarcoma: a systematic review of the literature. Kanjeekal S; Chambers A; Fung MF; Verma S Gynecol Oncol; 2005 May; 97(2):624-37. PubMed ID: 15863170 [TBL] [Abstract][Full Text] [Related]
27. Phase II study of paclitaxel in combination with carboplatin for patients with recurrent or persistent uterine sarcoma. Yoo HJ; Lim MC; Lim S; Park JY; Kang S; Park SY; Seo SS Arch Gynecol Obstet; 2012 Dec; 286(6):1529-35. PubMed ID: 22825691 [TBL] [Abstract][Full Text] [Related]
28. A phase 2 study of alisertib (MLN8237) in recurrent or persistent uterine leiomyosarcoma: An NRG Oncology/Gynecologic Oncology Group study 0231D. Hyman DM; Sill MW; Lankes HA; Piekarz R; Shahin MS; Ridgway MR; Backes F; Tenney ME; Mathews CA; Hoffman JS; Aghajanian C; Hensley ML Gynecol Oncol; 2017 Jan; 144(1):96-100. PubMed ID: 28094040 [TBL] [Abstract][Full Text] [Related]
29. Phase II experience with ifosfamide/mesna in gynecologic malignancies: preliminary report of Gynecologic Oncology Group studies. Sutton GP; Blessing JA; Photopulos G; Berman ML; Homesley HD Semin Oncol; 1989 Feb; 16(1 Suppl 3):68-72. PubMed ID: 2539647 [TBL] [Abstract][Full Text] [Related]
30. Treatment of metastatic uterine leiomyosarcoma with cisplatin, pirarubicin, and ifosfamide. Hirota Y; Miyamura K; Hayata T; Miyakawa I Gynecol Obstet Invest; 1997; 44(1):70-2. PubMed ID: 9251960 [TBL] [Abstract][Full Text] [Related]
31. Ifosfamide and doxorubicin in the treatment of advanced leiomyosarcomas of the uterus: a Gynecologic Oncology Group study. Sutton G; Blessing JA; Malfetano JH Gynecol Oncol; 1996 Aug; 62(2):226-9. PubMed ID: 8751554 [TBL] [Abstract][Full Text] [Related]
32. Phase II trial of cisplatin in the treatment of patients with advanced or recurrent mixed mesodermal sarcomas of the uterus: a Gynecologic Oncology Group Study. Thigpen JT; Blessing JA; Orr JW; DiSaia PJ Cancer Treat Rep; 1986 Feb; 70(2):271-4. PubMed ID: 3948191 [TBL] [Abstract][Full Text] [Related]
33. Mesna, doxorubicin, ifosfamide and dacarbazine chemotherapy for uterine leiomyosarcoma: a report of two cases. Minobe S; Todo Y; Suzuki Y; Aoyagi Y; Umazume T; Okamoto K; Kato H J Obstet Gynaecol Res; 2011 Jun; 37(6):645-9. PubMed ID: 21375676 [TBL] [Abstract][Full Text] [Related]
35. Phase II study of mitomycin, doxorubicin, and cisplatin in the treatment of advanced uterine leiomyosarcoma: a Gynecologic Oncology Group study. Edmonson JH; Blessing JA; Cosin JA; Miller DS; Cohn DE; Rotmensch J Gynecol Oncol; 2002 Jun; 85(3):507-10. PubMed ID: 12051882 [TBL] [Abstract][Full Text] [Related]